Omega Therapeutics Company Description
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company.
The company’s OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences.
It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury.
In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body.
Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. On February 10, 2025, Omega Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 94 |
| CEO | Kaan Certel |
Contact Details
Address: 20 Acorn Park Drive Cambridge, Delaware 02140 United States | |
| Phone | 617 949 4360 |
| Website | omegatherapeutics.com |
Stock Details
| Ticker Symbol | OMGAQ |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kaan Certel Ph.D. | President, Chief Executive Officer and Director |
| Dr. David A. Berry M.D., Ph.D. | Founder |
| Barbara Y. Chan CPA | Principal Financial Office, Principal Accounting Officer and Chief Accounting Officer |
| Dr. Jennifer Nelson Ph.D. | Chief Scientific Officer |
| Eva Stroynowski | Senior Vice President of Investor Relations and Corporate Affairs |
| Anthony Mullin | Chief People Officer |
| Charles O'Donnell Ph.D. | Vice President and Head of Computational Genomics and Data Sciences |
| Dr. Joe Newman Ph.D. | Senior Vice President of Early Discovery |